New Guidelines For Systemic Juvenile Idiopathic Arthritis
Systemic juvenile idiopathic arthritis is a form of juvenile idiopathic arthritis with systemic symptoms. Juvenile idiopathic arthritis is also known as juvenile rheumatoid arthritis [earlier name].
According to American College of Rheumatology, in US there are about 300,000 children who suffer from juvenile arthritis and other rheumatic illnesses.
Recently American College of Rheumatology has published in t Arthritis & Rheumatism and Arthritis Care & Research.
As defined by International League of Associations for Rheumatology, systemic juvenile idiopathic arthritis is defined as arthritis in one or more joints for at least six weeks in children with age 16 years or younger.
Systemic juvenile idiopathic arthritis accounts for 4% to 15% of all juvenile idiopathic cases.
Systemic juvenile idiopathic arthritis is either accompanied or preceded by daily fever for at least two-weeks that and one or more of following symptoms is also present.
- Red rash (evanescent erythematous rash),
- Enlarged liver, spleen or lymph nodes
- serositis [inflammation of the tissue lining] the lungs, heart, or stomach.
Treatment guidelines for systemic juvenile idiopathic arthritis were first introduced as separate entity in 2012. For developing update to these guidelined, investigators Dr. Pamela and colleagues conducted a systematic review of medical literature through January 2013.
They studied more than 1,200 clinical situations and developed recommendations for treatment of systemic juvenile arthritis and include recommendations use of the following medications:
- Non-steroidal anti-inflammatory drugs
- Intravenous immunoglobulin
- Calcineurin inhibitors
- Tumor necrosis factor alpha (TNF?) inhibitors
Article of recommendation can be downloaded from this link
Get more stuff on Musculoskeltal Health
Subscribe to our Newsletter and get latest publications on Musculoskeletal Health your email inbox.
Thank you for subscribing.